Nov 17, 2020 / 06:45PM GMT
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the Karyopharm team with us today. We're going to do a fireside chat to talk about Karyopharm. And with us, we've got Michael Kauffman, the CEO; Mike Mason, the CFO; and Ian Karp from Investor Relations.
So thanks, everyone, for joining us today. And maybe to start off, Michael, if you want to provide an intro to Karyopharm for those who might not be familiar with the story.
Michael G. Kauffman - Karyopharm Therapeutics Inc. - Co-Founder, CEO & Director
Sure. Karyopharm was founded in 2009, focused on modulating nuclear export from the cell nucleus and treating diseases like cancer and other abnormalities, including autoimmune disease and certain viruses. We have our lead product, it's called XPOVIO. It's now marketed for 2 indications. It entered the clinic as selinexor, a first-in-class oral inhibitor of the nuclear export, protein
Karyopharm Therapeutics Inc at Jefferies Virtual London Healthcare Conference Transcript
Nov 18, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers